| Literature DB >> 25169729 |
T Karaderi1, S M Keidel1, J J Pointon1, L H Appleton2, M A Brown3, D M Evans4, B P Wordsworth5.
Abstract
OBJECTIVES: ANTXR2 variants have been associated with ankylosing spondylitis (AS) in two previous genome-wide association studies (GWAS) (p∼9×10(-8)). However, a genome-wide significant association (p<5×10(-8)) was not observed. We conducted a more comprehensive analysis of ANTXR2 in an independent UK sample to confirm and refine this association.Entities:
Keywords: Ankylosing Spondylitis; Epidemiology; Gene Polymorphism; Inflammation; Spondyloarthritis
Mesh:
Substances:
Year: 2014 PMID: 25169729 PMCID: PMC4215346 DOI: 10.1136/annrheumdis-2014-205643
Source DB: PubMed Journal: Ann Rheum Dis ISSN: 0003-4967 Impact factor: 19.103
Associations of 9 ANTXR2 SNPs with AS in (1A) the independent replication study, (1B) HLA-B27-positive and (1C) HLA-B27-negative stratified analyses
| Replication study | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) All cases vs controls (2978 vs 8365) | (B) B27+ cases vs B27+ controls (1935 vs 696) | (C) B27– cases vs B27– controls (358 vs 7669) | |||||||||
| SNP | Minor allele | MAF (%) | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI |
| rs6534639 | C | 45/47 | 0.0005* | 0.90 | 0.85 to 0.95 | 0.09 | 0.90 | 0.79 to 1.02 | 0.01* | 0.83 | 0.71 to 0.96 |
| rs4234848 | G | 31/32 | 0.08 | 0.94 | 0.88 to 1.01 | 0.37 | 0.94 | 0.82 to 1.08 | 0.1 | 0.88 | 0.74 to 1.04 |
| rs11098965 | C | 24/25 | 0.2 | 0.96 | 0.89 to 1.03 | 0.19 | 0.91 | 0.79 to 1.05 | 0.4 | 0.93 | 0.78 to 1.11 |
| rs4444771 | G | 24/25 | 0.2 | 0.95 | 0.89 to 1.02 | 0.14 | 0.90 | 0.78 to 1.03 | 0.6 | 0.96 | 0.80 to 1.14 |
| rs12504282 | C | 43/46 | 0.0001* | 0.89 | 0.84 to 0.94 | 0.006* | 0.84 | 0.74 to 0.95 | 0.4 | 0.93 | 0.80 to 1.08 |
| rs10000471 | C | 33/35 | 0.01* | 0.92 | 0.86 to 0.98 | 0.03* | 0.87 | 0.76 to 0.99 | 0.1 | 0.88 | 0.75 to 1.04 |
| rs4640621 | A | 34/36 | 0.001* | 0.90 | 0.85 to 0.96 | 0.01* | 0.85 | 0.75 to 0.97 | 1.0 | 1.00 | 0.85 to 1.17 |
| rs4333130 | G | 34/36 | 0.002* | 0.91 | 0.85 to 0.97 | 0.02* | 0.86 | 0.75 to 0.98 | 1.0 | 1.00 | 0.85 to 1.17 |
| rs6839672 | A | 16/15 | 0.6 | 1.02 | 0.94 to 1.11 | 0.10 | 1.16 | 0.97 to 1.38 | 0.3 | 0.90 | 0.72 to 1.12 |
Nominally significant (p<0.05) associations are shown (*).
Number of cases and controls in each analysis is also shown in brackets. (B27: HLA-B27).
HLA, human leukocyte antigen; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Associations of ANTXR2 SNPs with AS in (2A) the overall meta-analysis, (2B) HLA-B27-positive and (2C) HLA-B27-negative stratified meta-analyses
| Meta-analysis | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) All cases vs controls (6001 vs 17 506) | (B) B27+ cases vs B27+ controls | (C) B27–cases vs B27–controls | ||||||||||
| SNP | p Value | OR | Cochran's Q | I2 (%) | p Value | OR | Cochran's Q | I2 (%) | p Value | OR | Cochran's Q | I2 (%) |
| rs6534639 | 4.5×10−6 | 0.91 | 0.77 | 0 | 0.08 | 0.93 | 0.52 | 0 | 0.13 | 0.92 | 0.08 | 60 |
| rs4234848 | 0.0007 | 0.92 | 0.59 | 0 | 0.01 | 0.89 | 0.44 | 0 | 0.57 | 0.97 | 0.24 | 30 |
| rs11098965 | 7.1×10−5 | 0.91 | 0.09 | 59 | 0.006 | 0.87 | 0.65 | 0 | 0.22 | 0.93 | 0.70 | 0 |
| rs4444771 | 6.4×10−5 | 0.91 | 0.11 | 54 | 0.005 | 0.87 | 0.74 | 0 | 0.35 | 0.94 | 0.75 | 0 |
| rs12504282 | 6.7×10−9 | 0.88 | 0.40 | 0 | 0.0003 | 0.85 | 0.74 | 0 | 0.56 | 0.97 | 0.68 | 0 |
| rs10000471 | 1.2×10−5 | 0.91 | 0.66 | 0 | 0.0004 | 0.85 | 0.81 | 0 | 0.40 | 0.95 | 0.47 | 0 |
| rs4640621 | 1.2×10−8 | 0.88 | 0.43 | 0 | 0.002 | 0.87 | 0.91 | 0 | 0.44 | 0.96 | 0.36 | 3 |
| rs4333130 | 2.5×10−8 | 0.88 | 0.35 | 5 | 0.003 | 0.88 | 0.95 | 0 | 0.44 | 0.96 | 0.36 | 2 |
| rs6839672 | 0.9 | 1.00 | 0.48 | 0 | 0.1 | 1.10 | 0.63 | 0 | 0.17 | 0.90 | 0.96 | 0 |
Three SNPs reached genome-wide significance (p<5×10−8) in the overall meta-analysis.
Number of cases and controls in each analysis is also shown in brackets. (B27: HLA-B27).
AS, ankylosing spondylitis; HLA, human leukocyte antigen; SNP, single nucleotide polymorphism.
Figure 1Forest plots for overall meta-analysis of 9 single nucleotide polymorphisms (SNPs). Plots for SNPs with highly significant p-values, rs12504282 (p=6.7×10−9), rs4640621 (p=1.2×10−8), rs4333130 (p=2.5×10−8) and rs6534639 (p=4.5×10−6) show agreement across the studies with overlapping CIs. Two SNPs rs11098965 (I2=59%, Cochran's Q p=0.09) and rs4444471 (I2=54%, Cochran's Q p=0.11) exhibit some degree of heterogeneity, but this was not statistically significant (p>0.05).
Figure 2Regional association plot showing ANTXR2 (CMG2) and all the single nucleotide polymorphisms (SNPs) in the study on the x-axis and their corresponding −log10p values on the y-axis. Historic sex-averaged recombination rates are also shown in blue (top panel). Linkage disequilibrium (r2, 1000 Genomes March 2012 European reference panel) between the top SNP rs12504282 (purple) and the other SNPs are also shown with colour-coding. ENCODE data showing that rs12504282 and the previous top genome-wide association studies (GWAS) SNPs are near a region of possible enhancer binding are presented in the bottom panel (A) Gene structure; (B) H3K27Ac mark, ie, often found near active regulatory elements; (C) DNaseI hypersensitivity clusters; (D) Transcription factor ChIP-seq; (E) Chromatin state segmentation; (F) Transcription factor binding sites by epitope-tag; G- Top SNPs from the previous GWAS (rs4333130 (TASC, 2010) and rs4389526 (WTCCC2, 2011)). These three top SNPs from three different studies are strongly correlated (rs4389526-rs4333130 r2=1.0, D′=1.0; rs4389526-rs12504282 r2=0.8, D′=1.0; rs4333130-rs12504282 r2=0.76, D′=1.0).